Literature DB >> 30776475

Impaired behavioural flexibility related to white matter microgliosis in the TgAPP21 rat model of Alzheimer disease.

Alexander Levit1, Aaron M Regis1, Andrew Gibson1, Olivia H Hough1, Shikhar Maheshwari1, Yuksel Agca2, Cansu Agca2, Vladimir Hachinski3, Brian L Allman1, Shawn N Whitehead4.   

Abstract

Executive dysfunction and white matter inflammation continue to be relatively understudied in rodent models of Alzheimer's disease (AD). Behavioural inflexibility is an important component of executive dysfunction that can be further categorized as perseverative or regressive, which respectively specify whether maladaptive persistence occurs early or late during a behavioural change. Previous studies of the TgAPP21 rat model of AD (expressing pathogenic hAPP) suggested a potentially spontaneous increase of regressive behavioral inflexibility. In this study, 7-8-month-old male TgAPP21 rats were tested for behavioral flexibility, learning, and memory using an operant conditioning chamber and the Morris Water Maze (MWM). TgAPP21 rats demonstrated a regressive behavioral inflexibility during set shifting in an operant conditioning chamber (regressive errors η2 = 0.32 and number of errors after criterion η2 = 0.33). Regressive behavior was also demonstrated in the MWM probe test, wherein TgAPP21 rats significantly increased their swim time in the target quadrant during the last third of the probe test (43% vs 33% in the first 2 thirds of the probe test or the Wt rats' 29%-32%); this behavioral phenotype has not been previously described in the MWM. TgAPP21 demonstrated further impairment of behavioural inflexibility as they committed a greater number of reversal errors in the operant conditioning chamber (η2 = 0.30). Diffuse microglia activation was increased in the white matter tracts of TgAPP21 (corpus callosum, cingulum, and internal capsule; η2 = 0.59-0.62), which was found to correlate with the number of reversal errors in the operant conditioning chamber (R2 = 0.42). As TgAPP21 rats do not spontaneously develop amyloid plaques but have been shown in previous studies to be vulnerable to the development of plaques, these rats demonstrate an important onset of cognitive change and inflammation in the pre-plaque phase of AD. TgAPP21 rats are also an instrumental model for studying the role and mechanism of white matter microglial activation in executive functioning. This is pertinent to clinical research of prodromal AD which has suggested that white matter inflammation may underlie impairment of executive functions such as behavioral flexibility.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; Amyloid precursor protein; Behavioral flexibility; Executive function; Microglia; Neuroinflammation; Regressive error; Reversal; White matter

Mesh:

Substances:

Year:  2019        PMID: 30776475     DOI: 10.1016/j.bbi.2019.02.013

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  9 in total

Review 1.  Preventing dementia by preventing stroke: The Berlin Manifesto.

Authors:  Vladimir Hachinski; Karl Einhäupl; Detlev Ganten; Suvarna Alladi; Carol Brayne; Blossom C M Stephan; Melanie D Sweeney; Berislav Zlokovic; Yasser Iturria-Medina; Costantino Iadecola; Nozomi Nishimura; Chris B Schaffer; Shawn N Whitehead; Sandra E Black; Leif Østergaard; Joanna Wardlaw; Steven Greenberg; Leif Friberg; Bo Norrving; Brian Rowe; Yves Joanette; Werner Hacke; Lewis Kuller; Martin Dichgans; Matthias Endres; Zaven S Khachaturian
Journal:  Alzheimers Dement       Date:  2019-07       Impact factor: 21.566

Review 2.  Proceedings from the Albert Charitable Trust Inaugural Workshop on white matter and cognition in aging.

Authors:  Farzaneh A Sorond; Shawn Whitehead; Ken Arai; Douglas Arnold; S Thomas Carmichael; Charles De Carli; Marco Duering; Myriam Fornage; Rafael E Flores-Obando; Jonathan Graff-Radford; Edith Hamel; David C Hess; Massafumi Ihara; Majken K Jensen; Hugh S Markus; Axel Montagne; Gary Rosenberg; Andy Y Shih; Eric E Smith; Alex Thiel; Kai Hei Tse; Donna Wilcock; Frank Barone
Journal:  Geroscience       Date:  2019-12-06       Impact factor: 7.713

Review 3.  White matter microglia heterogeneity in the CNS.

Authors:  Sandra Amor; Niamh B McNamara; Emma Gerrits; Manuel C Marzin; Susanne M Kooistra; Veronique E Miron; Erik Nutma
Journal:  Acta Neuropathol       Date:  2021-12-08       Impact factor: 17.088

Review 4.  Silymarin's Inhibition and Treatment Effects for Alzheimer's Disease.

Authors:  Hong Guo; Hui Cao; Xiaowei Cui; Wenxiu Zheng; Shanshan Wang; Jiyang Yu; Zhi Chen
Journal:  Molecules       Date:  2019-05-06       Impact factor: 4.411

Review 5.  Heterogeneity of microglia and their differential roles in white matter pathology.

Authors:  Janice Lee; Gen Hamanaka; Eng H Lo; Ken Arai
Journal:  CNS Neurosci Ther       Date:  2019-11-15       Impact factor: 5.243

6.  Hypertension and Pathogenic hAPP Independently Induce White Matter Astrocytosis and Cognitive Impairment in the Rat.

Authors:  Alexander Levit; Sonny Cheng; Olivia Hough; Qingfan Liu; Yuksel Agca; Cansu Agca; Vladimir Hachinski; Shawn N Whitehead
Journal:  Front Aging Neurosci       Date:  2020-04-15       Impact factor: 5.750

7.  Precocious White Matter Inflammation and Behavioural Inflexibility Precede Learning and Memory Impairment in the TgAPP21 Rat Model of Alzheimer Disease.

Authors:  Alexander Levit; Andrew Gibson; Olivia Hough; Youngkyung Jung; Yuksel Agca; Cansu Agca; Vladimir Hachinski; Brian L Allman; Shawn N Whitehead
Journal:  Mol Neurobiol       Date:  2021-07-07       Impact factor: 5.590

Review 8.  Inflammasome and Cognitive Symptoms in Human Diseases: Biological Evidence from Experimental Research.

Authors:  So Yeong Cheon; Jeongmin Kim; So Yeon Kim; Eun Jung Kim; Bon-Nyeo Koo
Journal:  Int J Mol Sci       Date:  2020-02-07       Impact factor: 5.923

Review 9.  TSPO imaging in animal models of brain diseases.

Authors:  Nadja Van Camp; Sonia Lavisse; Pauline Roost; Francesco Gubinelli; Ansel Hillmer; Hervé Boutin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-10       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.